Vizsgálati helyszín
Hospital Ruber Juan Bravo
Madrid, 28006, SpanyolországMég nincs intézményhez kötve
- 19futó vizsgálat
- 18lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 37 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis20 vizsgálat
- 2. fázis14 vizsgálat
- 4. fázis2 vizsgálat
- Állapot
- Lezárult18 vizsgálat
- Toboroz11 vizsgálat
- Fut, nem toboroz7 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- Bristol-Myers Squibb3 vizsgálat
- Hoffmann-La Roche3 vizsgálat
- MedSIR3 vizsgálat
- Eli Lilly and Company2 vizsgálat
- GlaxoSmithKline2 vizsgálat
- és még 22
Futó vizsgálatok
Toboroz
A trial to learn how safe elecoglipron is and how well it works in adults living with obesity or excess body weight with or without type 2 diabetes
2025-524688-19-00· 3. fázis· AstraZeneca AB· Forrás
Toboroz
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A Phase 3 Trial of K-924 HD in Participants with Hypercholesterolemia with Inadequate Response to EU-Marketed Pitavastatin 4 mg
2025-523739-20-00· 3. fázis· Kowa Co. Ltd.· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
NCT07227311· 2. fázis· GlaxoSmithKline· Forrás
Toboroz
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045· 3. fázis· Hoffmann-La Roche· Forrás
Még nem toboroz
Treatment for Ph-negative ALL for Adults up to 65 Years
NCT07443592· PETHEMA Foundation· Forrás
Contact: Aranzazu Alonso, Dr (principal investigator)
Toboroz
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
NCT07361302· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A study to evaluate acalabrutinib, in combination with the R-CHOP standard of care, for previously untreated mantle cell lymphoma in Spain.
2025-521152-34-00· 2. fázis· Astrazeneca Farmaceutica Spain S.A.· Forrás
Toboroz
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
NCT07059000· 3. fázis· Kedrion S.p.A.· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
NCT06047457· 3. fázis· Ipsen· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
NCT04777331· 2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455· 3. fázis· Eisai Inc.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
NCT06579105· 2. fázis· AstraZeneca· Forrás
Lezárult
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.
NCT06176560· 3. fázis· Faes Farma S.A.· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
NCT06335173· 2. fázis· Acumen Pharmaceuticals· Forrás
Fut, nem toboroz
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
NCT06047444· 3. fázis· Ipsen· Forrás
Lezárult
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
NCT05798520· 2. fázis· Biogen· Forrás
Lezárult
A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-resistant Prostate Cancer (TAMARACK)
NCT05551117· 2. fázis· Macrogenics Inc.· Forrás
Lezárult
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
NCT05803421· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED
NCT05520723· 2. fázis· MedSIR· Forrás
Lezárult
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
NCT05686070· 3. fázis· Bayer· Forrás
Fut, nem toboroz
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
NCT05588843· 2. fázis· Sanofi· Forrás
Lezárult
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
NCT05518123· 4. fázis· Pfizer· Forrás
Lezárult
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
NCT05509400· 4. fázis· Pfizer· Forrás
Lezárult
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
NCT05318976· 2. fázis· Inmune Bio, Inc.· Forrás
Lezárult
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
NCT04867616· 2. fázis· UCB Biopharma SRL· Forrás
Lezárult
ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL
NCT04603183· 2. fázis· MedSIR· Forrás
Lezárult
First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC
NCT04408118· 2. fázis· MedSIR· Forrás
Fut, nem toboroz
Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC
NCT05498896· 2. fázis· Queen Mary University of London· Forrás
Hibát jelzek